Showing 2 ideas for tag "a"

Goal 2: Reduce Human Disease

Does lowering circulating lipoprotein(a) levels influence cardiovascular outcomes?

A comprehensive research strategy and plan is needed to determine the most efficient, safe, cost-effective and widely applicable strategy to decrease circulating levels of lipoprotein(a) and to determine whether lowering circulating lipoprotein(a) levels will reduce the risk of developing cardiovascular disease such as a heart attack or a stroke as well as the progression of atherosclerosis or aortic stenosis.

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Critical Challenge (CC)

Details on the impact of addressing this CQ or CC

Approximately 20% of the population are characterized by elevated circulating levels of lipoprotein(a), regardless of age, gender or blood cholesterol levels. Estimates suggest that up to 90% of the variation in plasma lipoprotein(a) levels could be due to genetic factors, which makes lipoprotein(a) the most prevalent inherited risk factor for cardiovascular diseases (CVD). Large-scale genetic studies have shown that Lipoprotein(a) was the strongest genetic determinant of CVD such as atherosclerosis and aortic stenosis. Lipoprotein(a) is one of the strongest predictors of residual CVD risk and has been shown to improve CVD risk prediction in several population-based studies. Lipoprotein(a) is also one of the strongest known risk factors for spontaneous ischemic stroke in childhood.
A comprehensive research strategy aiming at identifying, evaluating interaction with other risk factors, treating and educating patients with elevated lipoprotein(a) levels would result in substantial reductions of health care costs in the US and around the globe by reducing the burden of CVD while simultaneously improving the quality of life of these patients.

Feasibility and challenges of addressing this CQ or CC

The list of pharmaceutical agents that reduce lipoprotein(a) levels is steadily increasing. There are approximately half a dozen strategies that have been shown to significantly and safely lower lipoprotein(a) levels. One of the challenges of this research strategy will be to determine which of these strategies represent the most efficient, safe, cost-effective and widely applicable approach to lower lipoprotein(a) levels and CVD outcomes.
Increasing awareness on lipoprotein(a) and CVD will also be of utmost importance for this effort as relatively few physicians perform lipoprotein(a) testing and even fewer patients are aware of their lipoprotein(a) level. The first sign of high lipoprotein(a) is often a heart attack or stroke. Our challenge will be to identify patients with high lipoprotein(a) that could be enrolled in trials of risk characterization and lipoprotein(a)-lowering.

Name of idea submitter and other team members who worked on this idea Sandra Revill Tremulis on behalf of the Lipoprotein(a) Foundation Scientific Advisory Board

Voting

235 net votes
297 up votes
62 down votes
Active

Goal 2: Reduce Human Disease

Prodromal symptoms and signs of a heart attack/acute coronary syndrome

Can early warning symptoms and signs of a heart attack (acute coronary syndrome) be quantified through standardized symptom surveys, biochemical measures, electrocardiographic, or other diagnostic means to enable earlier evaluation and treatment?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

If patients could detect symptoms that have been demonstrated prospectively to herald an impending heart attack and/or if there were sensitive biochemical, electrocardiographic, or other tests that could be performed by patients/bystanders (e.g., in the home setting), by emergency medical services personnel, primary care providers or others in community settings to assist with decision support about seeking intervention for early symptoms/signs of an acute coronary syndrome, this would potentially save thousands of lives from heart attacks and sudden cardiac death.

Feasibility and challenges of addressing this CQ or CC

Prodromal heart attack symptoms (waxing and waning of symptoms in advance of complete vessel occlusion) have not been prospectively described or quantified. The standard symptom constellations from epidemiologic surveys have been described for heart attack symptoms (ACS) though there is variability in symptom data collection among heart attack surveys as well. Also while there are biochemical tests for muscle damage (troponin), there is not a biochemical test for ischemia such as could be applied in the home or work setting. Similarly it would be helpful if a self-applied electrocardiogram by patients/bystanders could give a diagnosis of early ischemia (prior to occlusion) so patients could seek observational care.

Name of idea submitter and other team members who worked on this idea Mary Hand

Voting

-2 net votes
1 up votes
3 down votes
Active